

Manuscript no. HAEMATOL/2010/030759 entitled "Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab"

Authors: Michael S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst and Tuna Mutis

Information about the contributions of each person named as having participated in the study

- 1) **Guarantor(s)**, i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
- van der Veer MS, Phd student (first author), m.vanderveer-2@umcutrecht.nl.
 - Mutis T, MD, PHD (last author), t.mutis@umcutrecht.nl.
 - de Weers M, PHD, company representative, m.deweers@genmab.com.

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): "Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the **conception of the study**: van der Veer MS, Mutis T, de Weers M, Lokhorst HM, Parren PWHL.

3) **Design & Methods**. The following authors were responsible for specific investigations:

- Kessel B, experimental procedures and execution of full BM assays, and complement mediated assays.
- van der Weers MS, experimental execution of full BM assays and all cell line ADCC.
- Wittebol S, collection and initial analysis of BM material from patients.

4) **Results**. The following authors were responsible for specific portions of the results, including figures and tables :

- Kessel B, experimental procedures and execution of full BM assays, and complement mediated assays. Figure 3 and 4.
- van der Veer MS, experimental execution of full BM assays and cell line ADCC. Figure 1, 2, 5.

5) **Writing the manuscript**. The following authors were responsible for writing the manuscript:

- van der Veer MS, writing of the first draft.
- de Weers M, correcting drafts, input from company.
- Bakker JM, correcting drafts, patent investigation (scientific writer for Genmab).
- Parren PWHL, final editor for the drafts from Genmab B.V.
- Lokhorst HM, correcting, editing drafts
- Mutis T, correcting editing, rewriting all drafts, producing the final draft.

6) **Contributors Listed in Acknowledgments**:

UMC Utrecht and Genmab B.V. for providing research grants.